Davy James, Managing Editor

Insurance coverage and use of care improves among minorities following reform.

Michael Zeglinski, vice president of Specialty Pharmacy Operations at BriovaRx, discusses how specialty pharmacies can help patients manage increasing copay costs.

There may be several different disorders within Crohn's disease and ulcerative colitis.

Researchers seek a better understanding of the mechanism behind hepatocellular carcinoma.

Aggressive new approaches considered to curb financial hit from prescription drugs.

Revenue not expected to maintain pace of current immunology treatments.

Catch up with the most read articles of the week on Specialty Pharmacy Times.

Submission bolstered by trials evaluating biosimilar candidate in moderate-to-severe plaque psoriasis and rheumatoid arthritis.

Aggressive new approaches considered to curb financial hit from prescription drugs.

Severity and type of symptoms varies among cancer patients in different age groups.

Out-of-pocket costs to remain a significant hurdle for patients even after closing of coverage gap.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the trend of larger entities absorbing independent specialty pharmacies.

Bendeka was approved for indolent B-cell non-Hodgkin lymphoma that progressed during or within 6 months of treatment with a rituximab regimen.

Researchers weigh risk and reward in starting early antiretroviral therapy in patients with HIV.

Trial data shows positive results across a range of difficult-to-treat patients with MM.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses developing trends in specialty drug cost management.

An HCV vaccine, while elusive, offers the best hope to eradicate the virus.

Researchers consider the ramifications of using organs from infected patients to save lives.

New treatment option for patients who no longer respond to Xalkori.

Enhanced screening and treatment in high-risk populations could eliminate virus.

Top stories of the week on Specialty Pharmacy Times.

Researchers target how cancer cells avoid treatment.

CMS report shows spending rates are lower compared with the years prior to health care reform.

Treatment shows clinically meaningful reduction in the number of cancer cells in patients with relapsed or refractory chronic lymphocytic leukemia.

Addition of midostaurin to chemotherapy shows promise in patients with AML.

Rare disease can cause serious liver and cardiovascular conditions.

Addition of bortezomib to lenalidomide and low-dose dexamethasone therapy extends disease control.

Researchers determine how the liver is able to naturally inhibit HCV infection.

Potentially game changing drug may alter diabetes disease course.

David Lassen, chief clinical officer at Prime Therapeutics, discusses implications for specialty pharmacy from health care reform.